An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection

The development of more effective, accessible, and easy to administer COVID-19 vaccines next to the currently marketed mRNA, viral vector, and whole inactivated virus vaccines is essential to curtailing the SARS-CoV-2 pandemic. A major concern is reduced vaccine-induced immune protection to emerging...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Ley, Peter A., Zariri, Afshin, van Riet, Elly, Oosterhoff, Dinja, Kruiswijk, Corine P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721663/
https://www.ncbi.nlm.nih.gov/pubmed/34987509
http://dx.doi.org/10.3389/fimmu.2021.781280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721663/
https://www.ncbi.nlm.nih.gov/pubmed/34987509
http://dx.doi.org/10.3389/fimmu.2021.781280

Ejemplares similares